Dapagliflozin is a potent and selective sodium glucose cotransporter‐2 (SGLT2) inhibitor
which promotes urinary glucose excretion and induces weight loss. Since metabolic …

Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) cause substantially less weight
loss than would be expected based on their caloric deficits, probably due to enhanced …

Dapagliflozin is a potent and selective inhibitor of sodium–glucose co‐transporter type 2 that
is being developed for the treatment of type 2 diabetes mellitus. This open‐label …

Abstract Sodium/glucose cotransporter 2 (SGLT2) inhibitor improves systemic glucose
metabolism. To clarify the effect of dapagliflozin, we performed gene expression microarray …

Aims: To investigate whether glucose lowering with the selective sodium glucose transporter
2 (SGLT2) inhibitor dapagliflozin would prevent or reduce the decline of pancreatic function …

OBJECTIVE—The inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has
been proposed as a novel therapeutic approach to the treatment of diabetes. We have …

Background: With an increasing prevalence of obesity and metabolic syndrome, exploring
the effects and delineating the mechanisms of possible therapeutic agents are of critical …

Aims Sodium–glucose co‐transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal
proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 …

Obesity and obesity related kidney and liver disease have become more prevalent over the
past few decades, especially in the western world. Sodium-glucose cotransporter 2 (SGLT2) …

OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects
on cardiovascular and renal outcomes. The underlying mechanism may involve caloric …